Stayble Therapeutics AB

Equities

STABL

SE0013513652

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 14/06/2024 BST			5-day change	1st Jan Change
0.292 ^SEK	-5.81%		+9.77%	-3.63%

05-21	Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-20	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Stayble Therapeutics AB Announces Election of Erik Kinnman as Member of the Board of Directors

June 08, 2020 at 03:05 pm

Stayble Therapeutics AB (publ) announced new election of Erik Kinnman as member of the board of directors at its annual general meeting held on June 8, 2020. Erik Kinnman has broad leadership experience and expertise from various assignments in the life science sector and many years of experience from leading positions in pharmaceutical companies such as AstraZeneca and Sobi.

Latest news about Stayble Therapeutics AB

Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21	CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-20	CI
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	12-18	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Toleranzia Appoints Successor to Outgoing CFO	16/10/23	MT
Stayble Therapeutics Terminates Liquidity Provider Agreement	06/09/23	MT
Stayble Enters the First Patient in Herniated Disc Study	04/09/23	CI
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial	28/08/23	MT
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/08/23	CI
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.	21/08/23	CI
Stayble Therapeutics Phase IIb Study Nears the Final Line	24/07/23	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23	CI
Sweden's Stayble Therapeutics Appoints Chief Medical Officer	19/04/23	MT
Stayble Therapeutics AB Adds Disc Herniation to the Pipeline - Study Approved	07/03/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	21/02/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	21/02/23	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022	17/05/22	CI
Stayble Therapeutics to Continue Clinical Trial of Degenerative Disc Disease Drug in Russia; Shares Up 7%	14/03/22	MT
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22/02/22	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	18/11/21	CI
Stayble Therapeutics Presents Interim Results from the Phase IIb Study with STA363 Demonstrating Good Safety and Tolerability	10/11/21	CI
Stayble Therapeutics AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Stayble Therapeutics AB Elects Ulf Björklund as Chairman	03/06/21	CI

Chart Stayble Therapeutics AB

Duration

Period

More charts

Company Profile

Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
STAYBLE THERAPEUTICS AB	-3.63%	879K
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs